<DOC>
	<DOC>NCT01483534</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of Targeted Lung Denervation Therapy (or TLD TherapyTM) in patients suffering from COPD. Technical feasibility of the IPS SystemTM will also be evaluated through confirmation of successful application of TLD Therapy.</brief_summary>
	<brief_title>Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>FEV1 30% to 60% FEV1/FVC &lt;70% Prior smoker (at least 10 pack years) Quit smoking for at least 6 months Pulmonary hypertension, peripheral edema suggesting CHF or polycythemia Prior lung transplant, LVR, LVRS, median sternotomy, bullectomy or lobectomy Pulmonary nodule requiring surgery Presence of implantable electronic devices Active respiratory infection within recent weeks COPD exacerbation within recent weeks Recent Myocardial infarction (MI) Recent and unstable or life threatening arrhythmia Malignancy treated with radiation or chemotherapy within the last 2 years Presence or clinical diagnosis of other respiratory diseases other than COPD</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Intervention</keyword>
	<keyword>Device</keyword>
	<keyword>Denervation</keyword>
	<keyword>Lung</keyword>
	<keyword>Holaira, Inc.</keyword>
	<keyword>Innovative Pulmonary Solutions, Inc.</keyword>
</DOC>